Showing results (41-50 of 83) with videos related to
Sort By:
Pageof 9
Plos One|July 1, 2024
Correction: Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentAdam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.Cancer Immunology Research|June 7, 2014
Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockadeZachary A Cooper, Vikram R Juneja, Peter T Sage, et al.Plos One|October 14, 2015
Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentAdam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, et al.The Journal of Experimental Medicine|April 29, 2017
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibitionHelen L Young, Emily J Rowling, Mattia Bugatti, et al.Journal for Immunotherapy of Cancer|October 10, 2020
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumorsLillian Siu, Joshua Brody, Shilpa Gupta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2023
Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive TumorsLuana Guimaraes Sousa, Daniel J McGrail, Felippe Lazar Neto, et al.Cell Reports|June 2, 2015
Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 DeregulationHyungsoo Kim, Dennie T Frederick, Mitchell P Levesque, et al.Cancer Discovery|April 29, 2014
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitorsDavid J Konieczkowski, Cory M Johannessen, Omar Abudayyeh, et al.Plos One|July 2, 2014
Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimeticsDennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, et al.Nature|July 6, 2012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretionRavid Straussman, Teppei Morikawa, Kevin Shee, et al.Pageof 9